# Reversal of the Antithrombotic Action of New Oral Anticoagulants

> **NCT01478282** · PHASE4 · UNKNOWN · sponsor: **Gines Escolar** · enrollment: 10 (estimated)

## Conditions studied

- Thrombosis
- Anticoagulant-induced Bleeding
- Anticoagulant Overdosage
- Hemorrhage

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Dabigatran

## Key facts

- **NCT ID:** NCT01478282
- **Lead sponsor:** Gines Escolar
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478282, "Reversal of the Antithrombotic Action of New Oral Anticoagulants". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01478282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*